""For too long, the discharge letter has treated the patient as a courier—carrying a sealed document of Latin jargon to a GP they cannot reach. AI allows us to finally write for the patient, transforming a clinical handover into a personal recovery manual." Dr Sven Jungmann, co-founder and CEO of aiomics."
Moving beyond administrative automation, aiomics is now being used to transform the discharge letter—traditionally a jargon-heavy handover between doctors—into a patient-centric recovery plan. The new application tailors medical data to patients' education, life goals, and constraints, operationalizing the vision of Shared Decision Making advocated by Dr. Sven Jungmann and colleagues in recent white paper.

BERLIN - For generations, the medical discharge letter has treated the patient as little more than a courier. They leave the clinic carrying a sealed document written in Latin-heavy jargon—a technical handover intended for a general practitioner they may not see for weeks. This bureaucratic relic is now being dismantled by aiomics, a Berlin-based technology firm that is using artificial intelligence to transform clinical documentation into accessible, life-ready guidance.

Clinicians utilizing the aiomics platform are now generating patient letters that do far more than summarize a hospital stay. By ingesting existing clinical data—lab values, surgical notes, and medication plans—the software translates technical findings into a personalized narrative tailored to the patient’s specific educational background, professional constraints, and personal ambitions.

From "Jargon" to "Life Context"

The system’s ability to contextualize medical advice addresses a critical gap in health literacy. Where a standard letter might dryly note an elevated HbA1c level and recommend "lifestyle modification," the aiomics engine, under the supervision of the treating physician, generates specific, actionable advice. It might explain to a shift worker how to time meals to maintain blood sugar stability during nights, or offer a timeline to an avid gardener for when they can safely kneel again after a procedure. This approach operationalizes the concept of "contextualized care," moving beyond generic instructions to address the reality of the patient's daily life, whether that involves parenthood, frequent travel, or athletic goals.

This technological shift arrives alongside a significant academic contribution to the field. Dr. Sven Jungmann, CEO of aiomics, served as a lead author for the recently published white paper "Using AI for Shared Decision Making in Medicine" (2025). The paper, a collaborative effort involving the Independent Patient Council of Roche, experts from Google, clinician thought leaders, and patient representatives, argues that true shared decision-making is impossible when the patient cannot understand the information provided to them.

Operationalizing Shared Decision Making

The white paper, which has found success in Germany and is now available in English, posits that patient empowerment fails without accessible, personalized information. The aiomics platform effectively puts this theory into practice, solving the resource constraints that have historically made such personalization impossible. "We have long known that every patient deserves a letter written specifically for them, but clinicians simply lack the hours to produce it," notes an executive at a leading preventative care clinic. "This technology bridges that gap, allowing the doctor to provide the clinical facts while the software handles the labor of translation and personalization."

Crucially, the system is designed to function strictly as a communication interface rather than a diagnostic tool, ensuring compliance with Rule 11 of the EU Medical Device Regulation (MDR). It does not generate new medical diagnoses or treatment decisions; rather, it structures and explains the decisions already made by the physician. By focusing on health literacy and clarity, the platform empowers patients to understand and act upon their doctor's advice without entering the regulatory territory of a medical device.

A New Standard for Engagement

The impact of this shift extends across the spectrum of care, from acute recovery to chronic disease management and prevention. Early adopters report that by providing advice that respects the patient's reality, they are seeing higher levels of engagement and satisfaction. "The patient letter is often the most important document in a health journey, yet it has traditionally been the least useful to the person it concerns," says Dr. Jungmann. "We are seeing clinicians use our infrastructure to finally break the 'Latin barrier,' handing over not just a diagnosis, but a manual that fits the patient's actual life."

About aiomics

aiomics is a Berlin-based healthcare technology company building the operating system for high-performance medical teams. Founded by a medical doctor, a physicist, and a lawyer, the company provides infrastructure that automates administrative workflows and enhances clinical communication. Its technology is designed to support clinicians in delivering personalized, compliant, and patient-centric care. Dr. Sven Jungmann, CEO, is a lead author of the 2025 white paper Using AI for Shared Decision Making in Medicine.

Media Contact
Company Name: Aiomics GmbH
Contact Person: Dr. Sven Jungmann
Email: Send Email
Phone: 015792371115
Address:Rosenthaler Straße 72A
City: Berlin, 10119
Country: Germany
Website: https://www.aiomics.io/

 

Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: The End of the "Latin Courier": aiomics Reinvents the Patient Letter as a Personalized Health Manual

Information contained on this page is provided by an independent third-party content provider. XPRMedia and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact [email protected]